PRF Technologies Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The firm is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The firm also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.
PRF Technologies Ltd 주요 수익원은 North American Brokerage이며, 최신 수익 발표에서 수익은 684,873,000입니다. 지역별로는 United States이 PRF Technologies Ltd의 주요 시장이며, 수익은 573,658,000입니다.
PRF Technologies Ltd은 수익성이 있나요?
no, 최신 재무제표에 따르면 PRF Technologies Ltd의 순손실은 $0입니다.